RxDoctor Payments DataLook up a doctor →

Christen Alevizatos, MD

Urology · Baltimore, MDNPI 1154376325

Payments from drug & device makers

$16,572in general payments, 2019–2025

Across 625 payments — averaging $26.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • SN Holdings, LLC$3K
  • Sumitomo Pharma America, Inc.$2K
  • Boston Scientific$1K
  • Johnson & Johnson$1K
  • Bayer$898
  • Astellas Pharma US Inc$765
  • plus $8K from 52 others

What the payments were for

  • Speaking & faculty fees$1121%
  • Travel & lodging$2,53115%
  • Food & beverage$13,73983%
  • Education$1901%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,572 in reported general payments places this provider in the 80th percentile of 274 urology providers in Maryland.

See all urology providers in Maryland

Medicare billing

Part B allowed, 2024
$1,081,965
Medicare patients
981
Services billed
11,234

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide12$169,284
ErleadaApalutamide11$159,102
OrgovyxRelugolix54$157,896
MyrbetriqMirabegron84$75,508
GemtesaVibegron76$55,351
Testosterone35$8,305
Tamsulosin Hcl329$5,395
Oxybutynin Chloride ErOxybutynin Chloride126$3,705
Finasteride145$3,207
Potassium Citrate ErPotassium Citrate38$2,527
Alfuzosin Hcl ErAlfuzosin Hcl54$1,894
Methenamine Hippurate22$1,806
Tolterodine Tartrate ErTolterodine Tartrate20$1,759
Silodosin16$1,157
Estradiol17$855

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$765$244,79296 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$1,695$213,246130 claims
Johnson & JohnsonErleada$1,312$159,10211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 274 urology providers in Maryland.

Other urology in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →